Dr. Macartney has served as the Chairperson of our Board since May 2015 and as a member of our Board since May 2014. From January 2017 to June 2017, Dr. Macartney served as CEO of Scout Bio Inc., a gene therapy company developing therapies for companion animals. Dr. Macartney serves on the Board of Dechra PLC, an international animal health pharmaceutical company based in the United Kingdom, and on the Supervisory Board of the Netherlands Translational Research Centre, a preclinical biopharmaceutical company based in The Netherlands. He served as President, Chief Executive Officer and a member of the board of directors of Ambrx Inc., a biopharmaceutical company, from February 2013 to June 2015. Prior to Ambrx, Dr. Macartney served at Shire AG, a specialty biopharmaceutical company, as Senior Vice President of the Emerging Business Unit, where he was responsible for discovery initiatives through Phase 3 development of Shire’s Specialty Pharmaceutical portfolio. Prior to joining Shire AG, he served at GSK, a pharmaceutical company, from 1999 to 2011, serving as Senior Vice President of Global Product Strategy and Project/Portfolio Management from 2007 to 2011, as Senior Vice President, Cardiovascular and Metabolic Medicine Development Center from 2004 to 2007, and as Vice President, Global Head of Cardiovascular, Metabolic and Urology Therapeutic Areas from 1999 to 2004. Prior to joining GSK, Dr. Macartney was employed at Astra Pharmaceuticals in leadership roles in operations, marketing and sales, and served as Executive Director, Commercial Operations at AstraMerck, Inc., a pharmaceutical company. Dr. Macartney received his Ph.D. from Glasgow University in Scotland, where he was a Royal Society Research Fellow, and his B.V.M.S. (equivalent to a D.V.M.) from Glasgow University Veterinary School. He is also trained in diagnostic pathology and is a Fellow of the Royal College of Pathologists.
What is Lawson Macartney's net worth?
The estimated net worth of Lawson Macartney is at least $2.47 million as of November 8th, 2024. Dr. Macartney owns 47,965 shares of Viking Therapeutics stock worth more than $2,470,677 as of December 3rd. This net worth approximation does not reflect any other assets that Dr. Macartney may own. Learn More about Lawson Macartney's net worth.
How do I contact Lawson Macartney?
Has Lawson Macartney been buying or selling shares of Viking Therapeutics?
In the last ninety days, Lawson Macartney has sold $137,340.00 of Viking Therapeutics stock. Most recently, Lawson Macartney sold 2,000 shares of the business's stock in a transaction on Friday, November 8th. The shares were sold at an average price of $68.67, for a transaction totalling $137,340.00. Following the completion of the sale, the director now directly owns 47,965 shares of the company's stock, valued at $3,293,756.55. Learn More on Lawson Macartney's trading history.
Who are Viking Therapeutics' active insiders?
Are insiders buying or selling shares of Viking Therapeutics?
In the last year, insiders at the biotechnology company sold shares 19 times. They sold a total of 1,383,618 shares worth more than $81,779,033.02. The most recent insider tranaction occured on November, 8th when Director Lawson Macartney sold 2,000 shares worth more than $137,340.00. Insiders at Viking Therapeutics own 4.7% of the company.
Learn More about insider trades at Viking Therapeutics. Information on this page was last updated on 11/8/2024.
